Results 141 to 150 of about 209,011 (190)

Dyslipidemia in the era of HIV protease inhibitors

Progress in Cardiovascular Diseases, 2003
Human immunodeficiency virus protease inhibitors are associated with metabolic abnormalities that may increase risk of atherosclerotic vascular disease, including dyslipidemia, insulin resistance, and central obesity. Dyslipidemia, characterized by hypercholesterolemia and hypertriglyceridemia, small low- and high-density lipoprotein particles, and in ...
openaire   +2 more sources

Screening efficacy of available HIV protease inhibitors on COVID-19 protease

, 2020
M. Mirzaei, K. Harismah, M. Da'i, E. Salarrezaei, Zahra Roshandel   +4 more
semanticscholar   +1 more source

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

AIDS (London), 1998
A. Carr, K. Samaras, S. Burton, M. Law, J. Freund, D. Chisholm, D. Cooper   +6 more
semanticscholar   +1 more source

Ongoing trials in HIV protease inhibitors

Expert Opinion on Investigational Drugs, 2000
The development of antiretrovirals has led to a revolution in the care of patients infected with HIV. What was once a uniformly fatal syndrome has become a more treatable, chronic, infectious disease. Central to this revolution have been the protease inhibitors, a class of drugs with potent antiretroviral activity.
openaire   +2 more sources

A Comparison Study of Multiple Measures of Adherence to HIV Protease Inhibitors

Annals of Internal Medicine, 2001
Honghu Liu, C. Golin, L. Miller, R. Hays, C. Beck, Sam Sanandaji, J. Christian, Tomás Maldonado, Dena Duran, A. Kaplan, N. Wenger   +10 more
semanticscholar   +1 more source

Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors.

Science, 1994
PatrickY.-S. Lam, P. Jadhav, C. Eyermann, C. Hodge, Y. Ru, L. Bacheler, J. Meek, M. Otto, M. Rayner, Y. Nancy Wong   +9 more
semanticscholar   +1 more source

Advances in non-peptidomimetic HIV protease inhibitors.

Current Medicinal Chemistry, 2014
X. Pang, Z. Liu, G. Zhai
semanticscholar   +1 more source

Fifteen years of HIV Protease Inhibitors: raising the barrier to resistance.

Antiviral Research, 2010
A. Wensing, N. V. van Maarseveen, M. Nijhuis   +2 more
semanticscholar   +1 more source

IN VITRO INHIBITION OF UDP GLUCURONOSYLTRANSFERASES BY ATAZANAVIR AND OTHER HIV PROTEASE INHIBITORS AND THE RELATIONSHIP OF THIS PROPERTY TO IN VIVO BILIRUBIN GLUCURONIDATION

Drug Metabolism And Disposition, 2005
Donglu Zhang, T. Chando, D. Everett, C. Patten, S. Dehal, W. Humphreys   +5 more
semanticscholar   +1 more source

Boosting of HIV Protease Inhibitors by Ritonavir in the Intestine: The Relative Role of Cytochrome P450 and P-Glycoprotein Inhibition Based on Caco-2 Monolayers versus In Situ Intestinal Perfusion in Mice

Drug Metabolism And Disposition, 2012
N. Holmstock, P. Annaert, P. Augustijns
semanticscholar   +1 more source